Benralizumab Proves Noninferior to Mepolizumab for EGPA : vi

Treatment with benralizumab (Fasenra) achieved remission at 36 and 48 weeks at rates similar to those of mepolizumab (Nucala) in a head-to-head phase 3 trial of the two drugs.

Related Keywords

Philadelphia , Pennsylvania , United States , University Of Pennsylvania , Petera Merkel , , American College Of Rheumatology , Astrazeneca , American College , Birmingham Vasculitis Activity Score , Vascular Damage Index , Biologic Therapy , Remission , Coronavirus , 019 Novel Coronavirus , 019 Ncov , Uhan Coronavirus , Uman Coronavirus Hku1 , Uman Coronavirus Oc43 , Cov Oc43 , Uman Coronavirus 229e , Cov 229e , Vasculitis , Humanized Monoclonal Antibody , Evacizumab , Rastuzumab , Granulomatosis , Monoclonal Antibody , Etuximab , Ituximab , Asthma , Sthmatic , Headache , Arthralgia , Ainful Joint , Joint Pain , Blood , Eosinophils , O ,